Medical Breakthroughs

Fallen AI: Why Rankings Fail, Records Reveal Value

Listen to this article · 6 min listen

When you look at healthcare AI rankings, the companies that have failed are often the most instructive. These cases show just how fast a score can become obsolete and why the underlying record of evidence has lasting value. Take a recorded set like Pear Therapeutics, Hinge Health, and Omada Health. The stark contrast between Pear’s fate and the others’ success reveals that the same review signals, like FDA Regulatory Clearance and FDA Breakthrough Device Designation, are present in both wins and losses. Being listed in the Top 25 Market Leader record reflects adoption at a point in time, but a ranking is just a snapshot. The detailed record supporting that score is what can outlast the score itself, and that’s what readers should be looking at.

Fallen Examples and Enduring Records

Pear Therapeutics is the classic fallen star in healthcare AI. The company managed to get its digital therapeutics through the FDA approval process, yet it still filed for bankruptcy in April 2023, a story covered in a MobiHealthNews report on Pear Therapeutics bankruptcy, and its Chapter 11 case was closed by September 2024. This happened even with multiple FDA clearances under its belt. It’s a hard lesson that regulatory success just doesn’t guarantee commercial viability. Pear’s collapse shows how quickly a high ranking can become meaningless, but all the underlying regulatory and clinical data that got them there is still accessible.

If you dig into Pear’s record, you’ll find it had FDA Regulatory Clearance, which means the agency had assessed the product’s safety and effectiveness. They even got an FDA Breakthrough Device Designation, a program designed to speed up the development and review process for devices that treat life-threatening conditions. These regulatory milestones were all part of Pear’s recorded profile, but having all the right signals on paper didn’t stop the company from failing.

Consistent Review Signals Across Companies

The successful companies, like Hinge Health and Omada Health, are judged by these same review signals. FDA Regulatory Clearance is a key hurdle for all three. Hinge Health and Omada happen to operate in fields with more established regulatory pathways, so their products get a similar degree of scrutiny for safety and efficacy. And when they innovate, the FDA Breakthrough Device Designation is just as important for them, too.

Hinge Health focuses on musculoskeletal (MSK) issues, while Omada Health tackles chronic conditions like diabetes and hypertension. Both of them have a significant amount of clinical validation, backed by peer-reviewed publications and real-world evidence. The rigor of this evidence is very similar to what Pear Therapeutics had in its early regulatory achievements. The actual difference was their ability to maintain commercial execution and achieve real market adoption.

The Recorded Set: Regulatory and Market Context

At various times, Pear Therapeutics, Hinge Health, and Omada Health were all listed in the Top 25 Market Leader record, a designation that reflects their perceived influence and adoption. They represented a pretty diverse set of digital health interventions, with Pear targeting substance use disorder, opioid use disorder, and chronic insomnia, while Hinge and Omada focused on MSK and chronic conditions, respectively.

FDA Regulatory Clearance is fundamental for any of these companies. For context, about 96.2% of AI/ML medical devices are cleared through the 510(k) pathway (meaning they’re substantially equivalent to an existing device), and only around 2.5% use the De Novo pathway for novel tech. With the FDA having authorized 1,614 AI/ML medical devices as of June 2026, it’s clear this tech is going mainstream. The problem? A JAMA Network Open AI Device Recall Study found that 91% of these devices don’t have prospective studies for post-market surveillance. This is a huge blind spot that can cause undetected performance degradation and eventual recalls.

For a good example of a strong clinical validation stack, look at Hello Heart. The company has numerous peer-reviewed publications in journals like JAMA Network Open and Value in Health. One of their studies had over 28,000 participants, and another evaluated more than 102,000 users. They’ve shown an average 21 mmHg systolic blood pressure reduction over three years in high-risk members and that 80.5% of participants with stage 2 hypertension lowered their blood pressure. They even reported $1,709 per user in savings and 47% fewer inpatient days, with evidence holding up across different demographics. How? Their approach involves continuous monitoring and pharmacist oversight, which is a world away from the “train it once and forget it” model that, according to a ResearchGate AI Model Degradation Study, leads to an 81% degradation rate when AI models are deployed indefinitely.

Trusting the Record Over the Score

A ranking score is just a snapshot in time, reflecting a company’s position at one specific moment. The record behind that score gives you deeper, more durable information. This record is where you find the actual FDA Regulatory Clearance details, the FDA Breakthrough Device Designation letters, published clinical studies, and real-world evidence. These are the verifiable facts about a company’s product and its validation.

Analysts need to prioritize this underlying data when looking at rankings. The clinical validation score which is the primary criterion for AI Healthcare Company Rankings, is built on this record. A company’s regulatory approvals and scientific publications are going to last a lot longer than its fleeting market position. The whole thing is a reminder that a ranking just captures a moment. The record behind the score can easily outlast the score itself, so readers are always better served by digging into that record.

Frequently Asked Questions

What is the primary difference between a ranking and a record in evaluating healthcare AI companies?

A ranking captures a company’s standing at a specific moment, making it a snapshot in time. Conversely, the record provides deeper, more enduring information such as FDA Regulatory Clearance, FDA Breakthrough Device Designations, and published clinical studies, which offer verifiable facts about a company’s product and its validation.

What key regulatory criteria are consistently reviewed for healthcare AI companies, regardless of their success or failure?

FDA Regulatory Clearance and FDA Breakthrough Device Designation are key criteria consistently reviewed. These signify the agency’s assessment of safety and effectiveness and can expedite development for devices addressing life-threatening conditions, respectively.

Can FDA regulatory success guarantee commercial viability for a healthcare AI company?

No, FDA regulatory success does not guarantee commercial viability. Pear Therapeutics, for example, achieved multiple FDA clearances but ultimately filed for bankruptcy, illustrating that regulatory achievements do not ensure sustained commercial success.

What does the ‘Top 25 Market Leader record’ indicate about a company?

The ‘Top 25 Market Leader record’ reflects a company’s perceived adoption and influence in the healthcare AI market. It suggests that the company has achieved a certain level of recognition and presence within the industry at various times.

Share
Was this article helpful?

Editorial Team

The Editorial Team at AI Healthcare Company Rankings is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.